Revive Therapeutics (RVV.V) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19.
Today, Revive Therapeutics announced it has signed a collaboration agreement with Attwill Medical Solutions LP (“AMS”) for the clinical and commercial development of the Company’s next-generation lyophilized formulation of Bucillamine.
“The formulation development of our novel lyophilized formulation of Bucillamine at the University of Waterloo is near complete, and we are now entering into the next phase of our product development cycle and preparing for a clinical trial,” said Michael Frank, CEO of Revive. “AMS specializes in contract manufacturing of lyophilization and related processing of pharmaceuticals, making it an ideal partner for Revive in achieving its clinical and commercial objectives.”
AMS is one of the largest medical lyophilizers in the U.S., with cGMP facilities and dryers that can lyophilize volumes ranging from 1 to 2,000 liters per cycle. The collaboration between Revive and AMS will support the technology transfer of the lyophilized formulation of Bucillamine from the University of Waterloo (“UW”) to AMS.
After the technology transfer, AMS will begin the development and clinical trial manufacturing of lyophilized Bucillamine under GMP. The Company expects to have its novel lyophilized Bucillamine ready for clinical evaluation in 2024.
Revive and AMS will prepare plans for potential commercial scale-up to support public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. In addition, as a potent antioxidant and anti-inflammatory, Bucillamine may be helpful for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury.
For a more in-depth fundamental breakdown of Revive Therapeutics, be sure to check out Chris Parry’s latest article on the Company and its exciting story heading into 2024.
A classic range pattern.
The stock is testing its major support zone around $0.025. The stock should see buyers enter here to hold support. A daily close above $0.04 would be a good start for potential upwards momentum. The major resistance zone comes in at the $0.06 zone.
On November 20th 2023, bulls stepped in and printed a strong full bodied engulfing candle. This is a strong sign that buyers are here. If you look to July and August 2023, you can see that engulfing candles have led to bounces back to the $0.06 resistance zone.
So far a good start holding support and investors and market participants should watch for that break above $0.04.
